Results 1 to 10 of about 47,442 (285)

Cardiac amyloidosis

Swiss Medical Weekly
Cardiac amyloidosis is a disease characterised by the accumulation of amyloid protein in the heart tissue. There are several types of amyloidosis, but the most common types affecting the heart are ATTR amyloidosis (caused by transthyretin protein) and ...
Natallia Laptseva, Dominik C. Benz, Rahel Schwotzer, Andreas J. Flammer   +3 more
doaj   +7 more sources

Role of cardiac MRI in the diagnosis of cardiac amyloidosis. Clinical cases

Клинический разбор в общей медицине, 2021
Purpose. The aim of this work is to show the capabilities of late gadolinium enhancement cardiac magnetic resonance imaging (MRI) in the diagnosis of a rare disease such as cardiac amyloidosis. Materials and methods.
Ekaterina A. Butorova , Olga V. Stukalova   +1 more
doaj   +2 more sources

Cardiac amyloidosis presenting as recurrent acute coronary syndrome with unobstructed coronary arteries: Case report

Indian Heart Journal, 2015
Amyloidosis is a systemic disorder characterized by the deposition of mis-folded protein molecules within various organs. Cardiac involvement may be the presenting feature of this condition or may be identified incidentally during investigation for ...
Anish George, Brian McClements
doaj   +2 more sources

Base-to-apex gradient pattern of cardiac impairment identified on myocardial T1 mapping in cardiac amyloidosis

Radiology Case Reports, 2019
Late gadolinium enhancement imaging by cardiac magnetic resonance imaging (CMR) is the most reliable method for identifying cardiac involvement in patients with amyloidosis, and myocardial T1 mapping is a novel CMR technique that enables the noninvasive ...
Seitaro Oda, MD, PhD, Yawara Kawano, MD, PhD, Yutaka Okuno, MD, PhD, Daisuke Utsunomiya, MD, PhD, Takeshi Nakaura, MD, PhD, Kenichi Tsujita, MD, PhD, Yasuyuki Yamashita, MD, PhD   +6 more
doaj   +2 more sources

Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis

Transplantation Direct, 2022
Background. Heart transplantation in cardiac amyloidosis (CA) patients is possible and generally considered for transplantation if other organs are not affected.
Soulef Guendouz, MD, Philippe Grimbert, MD, PhD, Costin Radu, MD, PhD, Daniel Cherqui, MD, PhD, Chady Salloum, MD, Nicolas Mongardon, MD, PhD, Sami Maghrebi, MD, Karim Belhadj, MD, Fabien Le Bras, MD, Emmanuel Teiger, MD, PhD, Jean-Paul Couetil, MD, PhD, Adriana Balan, MD, Mounira Kharoubi, MSc, Mélanie Bézard, MSc, Silvia Oghina, MD, Diane Bodez, MD, PhD, Luc Hittinger, MD, PhD, Vincent Audard, MD, PhD, Violaine Planté-Bordeneuve, MD, PhD, Alexandre De la Taille, MD, PhD, Eric Bergoend, MD, Valerie Frenkel, MD, PhD, Pascale Fanen, MD, PhD, Vincent Leroy, MD, PhD, Christophe Duvoux, MD, PhD, Maryvonnick Carmagnat, PharmD, Thierry Folliguet, MD, PhD, Thibaud Damy, MD, PhD   +27 more
doaj   +1 more source

A case of cardiac amyloidosis incidentally detected by bone scintigraphy [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2021
A 73-year-old man with lung cancer underwent bone scintigraphy for disease staging. Diffuse myocardial technetium hydroxymethylene diphosphonate (99mTc-HMDP) uptake was incidentally found.
Hiroki Tanaka, Makoto Hosono, Mitsunori Kanagaki, Marina Shimizu, Naoko Matsubara, Kazuna Kawabata, Tadashi Miyamoto, Kazumi Itoi   +7 more
doaj   +1 more source

Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis

eJHaem, 2022
The causal protein of amyloid light‐chain (AL) amyloidosis is a monoclonal immunoglobulin free light chain (mFLC), which must be quantified in the serum for patient diagnosis and monitoring.
Hajer Abroud, Asma Beldi‐Ferchiou, Vincent Audard, François Lemonnier, Fabien Le Bras, Karim Belhadj, Anissa Moktefi, Elsa Poullot, Khalil El Karoui, Jehan Dupuis, Alizée Maarek, Louise Roulin, Marie‐Hélène Delfau‐Larue, Silvia Oghina, Mounira Kharoubi, Mélanie Bézard, Amira Zaroui, Thibaud Damy, Valérie Molinier‐Frenkel   +18 more
doaj   +1 more source

Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients

Biomedicines, 2022
Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis.
Mathijs O. Versteylen, Maaike Brons, Arco J. Teske, Marish I. F. J. Oerlemans   +3 more
doaj   +1 more source

Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021

Diagnostics, 2021
Cardiac amyloidosis is caused by the deposition of misfolded protein fibrils into the extracellular space of the heart. The diagnosis of cardiac amyloidosis remains challenging because of the heterogeneous manifestations of the disease.
Weijia Li, Dipan Uppal, Yu Chiang Wang, Xiaobo Xu, Damianos G. Kokkinidis, Mark I. Travin, James M. Tauras   +6 more
doaj   +1 more source

Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis

Annals of Noninvasive Electrocardiology, 2022
Background Cardiac amyloidosis is a protein misfolding disorder involving deposition of amyloid fibril proteins in the heart. The associated fibrosis of the conduction tissue results in conduction abnormalities and arrhythmias.
Perryn Lin Fei Ng, Yoke Ching Lim, Lauren Kay Mance Evangelista, Raymond Ching Chiew Wong, Ping Chai, Ching Hui Sia, Hoi Yin Loi, Tiong Cheng Yeo, Weiqin Lin   +8 more
doaj   +1 more source